West Pharmaceutical Services Inc. (NYSE:WST) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $81.80 and last traded at $81.80, with a volume of 97,633 shares traded. The stock had previously closed at $80.96.

A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $81.00 price objective for the company in a research report on Wednesday, April 20th. Jefferies Group reaffirmed a “hold” rating on shares of West Pharmaceutical Services in a research report on Thursday. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and issued a $90.00 price objective (up from $69.00) on shares of West Pharmaceutical Services in a research report on Friday, May 13th.

The firm’s 50-day moving average price is $77.27 and its 200-day moving average price is $69.47. The company has a market capitalization of $5.98 billion and a PE ratio of 59.53.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. During the same period last year, the business earned $0.47 earnings per share. The business had revenue of $388 million for the quarter, compared to analysts’ expectations of $384.58 million. The company’s revenue was up 7.9% on a year-over-year basis. On average, analysts anticipate that West Pharmaceutical Services Inc. will post $2.23 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 3rd. Investors of record on Wednesday, July 20th were given a dividend of $0.12 per share. The ex-dividend date was Monday, July 18th. This represents a $0.48 dividend on an annualized basis and a yield of 0.59%.

In other West Pharmaceutical Services news, Director Thomas W. Hofmann sold 2,466 shares of West Pharmaceutical Services stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $73.57, for a total value of $181,423.62. Following the completion of the transaction, the director now directly owns 34,506 shares of the company’s stock, valued at $2,538,606.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel Malone sold 3,950 shares of West Pharmaceutical Services stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $74.95, for a total transaction of $296,052.50. Following the completion of the transaction, the vice president now directly owns 30,666 shares of the company’s stock, valued at $2,298,416.70. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have recently modified their holdings of the company. RS Investment Management Co. LLC boosted its position in shares of West Pharmaceutical Services by 7.6% in the fourth quarter. RS Investment Management Co. LLC now owns 1,921,695 shares of the company’s stock valued at $115,724,000 after buying an additional 136,400 shares during the period. Vanguard Group Inc. boosted its position in shares of West Pharmaceutical Services by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 5,321,348 shares of the company’s stock valued at $320,452,000 after buying an additional 46,295 shares during the period. First Trust Advisors LP boosted its position in shares of West Pharmaceutical Services by 104.5% in the fourth quarter. First Trust Advisors LP now owns 24,581 shares of the company’s stock valued at $1,480,000 after buying an additional 12,560 shares during the period. Principal Financial Group Inc. boosted its position in shares of West Pharmaceutical Services by 2.8% in the fourth quarter. Principal Financial Group Inc. now owns 226,582 shares of the company’s stock valued at $13,645,000 after buying an additional 6,187 shares during the period. Finally, GSA Capital Partners LLP boosted its position in shares of West Pharmaceutical Services by 17.9% in the fourth quarter. GSA Capital Partners LLP now owns 17,134 shares of the company’s stock valued at $1,032,000 after buying an additional 2,601 shares during the period.

West Pharmaceutical Services, Inc is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s products include stoppers and seals for vials, prefillable syringe components and systems, components for intravenous and blood collection systems, safety and administration systems, advanced injection systems, and contract design and manufacturing services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.